Since the discovery of the lipostatic hormone leptin in 1994(Reference Zhang, Proenca, Maffei, Barone, Leopold and Friedman1), a wide diversity of protein signals and factors, known as adipokines, have been found to be secreted from white adipose tissue (WAT)(Reference Trayhurn and Beattie2–Reference Trayhurn and Wood4). This has greatly expanded the classical view of the tissue as a simple lipid storage organ to encompass a major secretory role. One intriguing protein produced by WAT is angiopoietin-like factor 4 (Angplt4), a secreted glycoprotein(Reference Kim, Kim, Kim, Kim, Park, Uhm, Lee and Koh5). Angplt4 was first identified as a target of the nuclear receptor family PPAR(Reference Kersten, Mandard, Tan, Escher, Metzger, Chambon, Gonzalez, Desvergne and Wahli6, Reference Yoon, Chickering, Rosen, Dussault, Qin, Soukas, Friedman, Holmes and Spiegelman7), and although expression has been detected in a number of tissues, it is notably high in WAT, brown adipose tissue and the placenta(Reference Kim, Kim, Kim, Kim, Park, Uhm, Lee and Koh5–Reference Lee, Seo, Kim and Kim8). Sequence analysis has shown that it is closely related to Angptl3, a protein exclusively expressed within the liver(Reference Conklin, Gilbertson, Taft, Maurer, Whitmore, Smith, Walker, Chen, Wattler, Nehls and Lewis9), with both proteins containing a coiled-coil domain near their N-terminus and a fibrinogen-like domain near the C-terminus(Reference Ge, Cha, Gopal, Harp, Yu, Repa and Li10).
Angplt4 was first identified in adipose tissue as a fasting-induced adipose factor (FIAF), that was substantially up-regulated during fasting(Reference Kersten, Mandard, Tan, Escher, Metzger, Chambon, Gonzalez, Desvergne and Wahli6), raising the possibility that it could play a major role in signalling nutritional deprivation. Subsequent studies have not only connected this adipokine (which we refer to as Angptl4/FIAF) with a putative role in energy regulation(Reference Kersten, Mandard, Tan, Escher, Metzger, Chambon, Gonzalez, Desvergne and Wahli6, Reference Yoshida, Shimizugawa, Ono and Furukawa11–Reference Yu, Burgess, Ge, Wong, Nassem, Garry, Sherry, Malloy, Berger and Li14), but also in angiogenesis(Reference Le Jan, Amy and Cazes15, Reference Hermann, Pinkerton, Jennings, Yang, Grom, Sowders, Kersten, Witte, Hirsch and Thornton16). Administration of Angptl4/FIAF by intravenous injection or by adenoviral-mediated over-expression dramatically raises plasma TAG levels, an effect mediated by reduced VLDL clearance due to the potent inhibition of lipoprotein lipase (LPL) activity(Reference Yoshida, Shimizugawa, Ono and Furukawa11, Reference Ge, Yang, Yu, Pourbahrami and Li12, Reference Yu, Burgess, Ge, Wong, Nassem, Garry, Sherry, Malloy, Berger and Li14, Reference Hermann, Pinkerton, Jennings, Yang, Grom, Sowders, Kersten, Witte, Hirsch and Thornton16). With respect to angiogenesis, it was found that Angptl4/FIAF stimulates nodule expression when grafted on to chick chorioallantoic membranes(Reference Le Jan, Amy and Cazes15) and also to stimulate in vitro tube formation of pulmonary artery endothelial cells and angiogenesis in mice(Reference Zhu, Li, Qin, Yang, He, Wan and Gu17). Angptl4/FIAF has also been shown to be up-regulated in conditions that promote angiogenesis(Reference Hermann, Pinkerton, Jennings, Yang, Grom, Sowders, Kersten, Witte, Hirsch and Thornton16, Reference Ifon, Pang, Johnson, Cashman, Zimmerman, Muralidhar, Chan, Casey and Rosenthal18), being increased in hypoxia(Reference Le Jan, Amy and Cazes15, Reference Belanger, Lu, Date, Liu, Vincent, Akita, Cheng, Gregory and Jiang19) and in some cancer cell lines(Reference Lee, Seo, Kim and Kim8, Reference Le Jan, Amy and Cazes15). Although identified as a target for PPAR, changes in Angptl4/FIAF expression are also mediated through other pathways; HIF-1α and the PPAR agonist Wy14643 act synergistically in neonatal rat cardiomyocytes(Reference Belanger, Lu, Date, Liu, Vincent, Akita, Cheng, Gregory and Jiang19) and regulation by PPAR-α in the liver of mice has been shown to be lost with fasting(Reference Kersten, Mandard, Tan, Escher, Metzger, Chambon, Gonzalez, Desvergne and Wahli6).
Despite the strong expression of Angptl4/FIAF in WAT, together with the high LPL activity in the tissue, little is known of the regulation of this adipokine. Nor is it clear whether there are major differences between the various fat depots, particularly in response to fasting; for a number of adipokines, distinct depot-dependent expression profiles are evident(Reference Oliver, Pico and Palou20, Reference Oliver, Pico, Serra and Palou21). In the present study, we show that there is strong Angptl4/FIAF expression in each WAT depot, but surprisingly fasting did not stimulate expression in any depot examined, despite a substantial fasting-induced increase in expression in liver and skeletal muscle. 3T3-L1 cells were then used to gain insight into the key regulators of a Angptl4/FIAF expression in adipocytes. The cell culture studies indicate that Angptl4/FIAF expression in adipocytes is strongly stimulated by the pro-inflammatory PGD2 as well as by the PPARγ agonist, rosiglitazone.
Material and methods
Animals
Adult male CD-1 mice, aged 9 weeks, were obtained from Charles River (UK). The mice were individually housed in a temperature-controlled room (21°C) with a 12 h–12 h light–dark cycle (lights on at 07.00 hours). The animals were fed a commercial rodent diet (CRM Diet, Labsure, UK) containing 19·2 % protein and 4·3 % lipid (w/w). Both food and water were available ad libitum. Fasted mice were deprived of food for 18 h, starting at 17.00 hours. Both fed and fasted animals were killed by cervical dislocation, and the following tissues were rapidly removed and frozen in liquid nitrogen: liver, muscle and three WAT depots (subcutaneous, epididymal and perirenal). All tissues were stored at − 80°C until analysis.
Cell culture
3T3-L1 cells (American Type Culture Collection, USA) were maintained and cultured as previously(Reference Peeraully, Jenkins and Trayhurn22). In brief, cells were cultured at 37°C in a humidified atmosphere of 5 % CO2–95 % air. Preadipocytes were maintained in culture medium containing Dulbecco's modified Eagle's medium (Invitrogen, UK) supplemented with 10 % (v/v) fetal calf serum (Sigma, UK). Differentiation was initiated 24 h after confluence by incubation for 2 d in culture medium containing 0·25 μm-dexamethasone, 0·5 mm-3-isobutyl-1-methylxanthine and 5 mg/μl insulin (Sigma). Subsequently, the cells were maintained in feeding medium consisting of culture medium (Dulbecco's modified Eagle's medium plus fetal calf serum) containing 5 μg/ml insulin for up to 20 d.
To study the time course of the expression of Angptl4/FIAF, cells were collected every 1–2 d. The effects of agents were tested on cells that were 10–12 d after the induction of differentiation. Before treatment (24 h) the media was changed and the cells were pre-incubated for 24 h in feeding media (Dulbecco's modified Eagle's medium plus fetal calf serum), insulin-free feeding medium (for the study on the effects of insulin) or fetal calf serum-free feeding medium (treatment medium for rosiglitazone, cytokines, PG). Cells were then treated with medium containing each of the specific agents to be tested: rosiglitazone (low dose 0·1 μm, high dose 1 μm; GlaxoSmithKline, UK), insulin (1 μm, 10 μm), dexamethasone (2 nm, 20 nm), leptin (0·1 μm, 2 μm), IL-6 (1 ng/ml, 25 ng/ml) (Sigma), noradrenaline (0·1 μm, 1 μm; Fluka, Switzerland), IL-1β (5 ng/ml, 20 ng/ml), IL-10 (5 ng/ml, 20 ng/ml) (PeproTech EC, UK), IL-18 (100 ng/ml, 500 ng/ml; R&D Systems, USA), PGE2, PGF2α and PGD2 (50 μm and 100 μm); PGI2 (50 μm and 150 μm) (Alexis Chemicals, UK). The control cells underwent the same procedure as treated cells, but no agent was added. Cells were collected in 700 μl Trizol (Invitrogen) at 24 h after the addition of the various agents. Medium was also collected and centrifuged at 1000 rpm for 10 min, the supernatant being stored together with the cells at − 80°C until use.
The dose response of the effects of PGD2 and its derivatives on Angptl4/FIAF expression were studied by treating cells with different concentrations of PG for 24 h.
RT-PCR
Total RNA was extracted with Trizol (Invitrogen) and any genomic DNA contamination was removed using a DNA-free kit (Ambion, UK), in accordance with the manufacturer's instructions. The concentration of each sample was determined from the absorbance at 260 nm.
Total RNA (1 μg) was reverse-transcribed to cDNA in a 20 μl reaction volume with anchored oligo(dt) primer using a Reverse-iT™ 1st Strand Synthesis Kit (Abgene, UK). Each cDNA sample (1 μl) was then amplified in a PCR mixture containing 0·02 mm of each primer and 1·1 × Reddy Mix PCR Master Mix (Abgene) in a final volume of 25 μl. Mouse β-actin was used as a housekeeping gene. The primer pairs used and the PCR conditions are as follows. Mouse Angptl4/FIAF (531 bp product): 5′-3′ TTC CAA CGC CAC CCA CTT ACA (sense); 5′-3′ ACCAAACCACCAGCCACCAGA (anti-sense); annealing temperature 58°C; twenty-eight cycles. Mouse β-actin (463 bp product): 5′-3′ TGCTGTCCCTGTATGCCTCT (sense); 5′-3′ AGGTCTTTACGGATGTCAACG (anti-sense); annealing temperature 60°C; twenty-four cycles. Mouse leptin (394 bp product): 5′-3′ CTGTCTTATGTTCAAGCAGTGCCTAT (sense); 5′-3′ AAGCCACCACCTCTGTGGAGTA (anti-sense); annealing temperature 62°C; thirty-five cycles. Mouse adiponectin (430 bp product): 5′-3′ TTAATCCTGCCCAGTCATGCCG (sense); 5′-3′ AGAACTTGCCAGTGCTGCCGTC (anti-sense); annealing temperature 62°C; thirty cycles.
PCR was performed on a thermal cycler (Hybaid, UK) with an initial denaturation at 94°C for 2 min followed by cycles consisting of denaturation at 94°C for 20 s, annealing at the specified temperature for 30 s and extension at 72°C for 40 s; the final step was an extension at 72°C for 5 min. PCR products were separated on a 1 % agarose gel stained with ethidium bromide. The PCR products were sequenced commercially to confirm their identity (MWG Biotech, Germany).
Real-time PCR
Relative Angptl4/FIAF expression was quantified using the 2− ΔΔCt method with either an ABI Prism 7700 Sequence detector (Applied Biosystems, USA) or a Stratagene MX3005P instrument (Stratagene, The Netherlands). All sample values were normalised against β-actin values and the results expressed as fold changes of threshold cycle (Ct) value relative to controls. Primer and probe sequences were designed using Primer Express software (Applied Biosystems). Primers and probes were synthesised commercially (Eurogentec, UK). Sequences were as follows. Mouse Angptl4/FIAF (110 bp product): 5′-3′ GGGACCTTAACTGTGCCAAGAG (sense); 5′-3′ GGAAGTATTGTCCATTGAGATTGG A (anti-sense), 5′-3′ FAM-CTCTCTGGTGGC TGGTGGTTTGGTAC-TAMRA (probe). Mouse β-actin (71 bp product): 5′-3′ ACGGCCAGGTCATCACTATTG (sense), 5′-3′ CAA GAAGGAAGGCTGGAAAAG (anti-sense), 5′-3′ FAM-ACGAGCGGTTCCGATGCCCTG-TAMRA (probe).
Amplification was performed in a ninety-six-well plate using a mix made from a qPCR core Kit (Eurogentec), with 900 nm forward and 900 nm reverse primers, 200 nm (225 nm in the case of the β-actin) probe and 1 μl cDNA to a final volume of 25 μl. For analysis on the Stratagene instrument, the same concentrations were used, but only 0·5 μl cDNA was added to a final volume of 12·5 μl. Each sample was run at least in duplicate for both Angptl4/FIAF and β-actin. Amplifications were performed commencing with a 2 min activation stage at 50°C, denaturation at 95°C for 10 min followed by forty cycles of denaturation at 95°C for 15 s and combined annealing and extension at 60°C for 1 min. Data were recorded and analysed with Sequence Detector software (Applied Biosystems or Stratagene).
Western blotting
To collect protein from culture media, samples of medium were incubated with TCA to a final concentration of 12·5 % for 3 h on ice and then centrifuged at 12 000 g for 30 min at 4°C. The protein pellet was dissolved in 1 % SDS. The protein concentration was determined using the bicinchoninic acid assay(Reference Wiechelman, Braun and Fitzpatrick23).
A polyclonal antibody was raised, using Eurogentec's Double X program, against the epitopes KGKDAPFKDSEDRVP and QSWEAYKDGFGDPQG present in the N- and C-terminal regions of mouse Angptl4/FIAF protein, respectively. Samples of protein were separated by SDS–PAGE on 10 % polyacrylamide gels. The proteins were then transferred to nitrocellulose membranes (Hybond C; Amersham Pharmacia, UK) and immunoblotting was performed overnight at 4°C. A rabbit polyclonal antibody to mouse Angptl4/FIAF was generated commercially (Eurogentec) and employed at a 1:500 dilution in Tris-buffered saline (pH 7·4) containing 0·1 % Tween and 7 % dried milk. Blots were then incubated for 1 h at room temperature with a sheep anti-rabbit secondary antibody conjugated to horseradish peroxidase (Santa Cruz Biotechnology, USA) at a 1:1000 dilution. Signals were detected with the enhanced chemiluminescence system (Amersham Pharmacia).
Statistical analysis
The statistical significance of differences between tissues or groups of treated cells was assessed by Student's unpaired t test; differences were considered to be significant when P < 0·05.
Results
Expression of angiopoietin-like protein 4/fasting-induced adipose factor in different adipose tissue depots
In the initial studies, the expression of Angptl4/FIAF was examined in different WAT depots by RT-PCR. A single band of approximately 531 bp was detected (Fig. 1 (a)) and the identity of this band as mouse Angptl4/FIAF was confirmed by sequencing. Angptl4/FIAF was expressed in each of the five major WAT depots examined (subcutaneous, epididymal, omental, mesenteric and perirenal), as well as in interscapular brown adipose tissue. There was also a strong signal in the liver, and faint bands were additionally observed in the brain, small intestine, kidney and lung, tissues in which Angptl4/FIAF is known to be also expressed(Reference Kersten, Mandard, Tan, Escher, Metzger, Chambon, Gonzalez, Desvergne and Wahli6, Reference Yoon, Chickering, Rosen, Dussault, Qin, Soukas, Friedman, Holmes and Spiegelman7, Reference Backhed, Ding, Wang, Hooper, Koh, Nagy, Semenkovich and Gordon24, Reference Wiesner, Morash, Ur and Wilkinson25).
Angiopoietin-like protein 4/fasting-induced adipose factor (Angptl4/FIAF) expression in mouse tissues. (a) Expression of Angplt4 in a range of mouse tissues, including five white adipose tissue depots, by RT-PCR. (b) Quantitation of Angptl4/FIAF mRNA levels by real-time PCR in mouse tissues. (c) Angptl4/FIAF expression by RT-PCR in mature adipocytes (adip) and stromal vascular (sv) cells isolated from subcutaneous (Sub), perirenal (Peri) and epididymal (Epi) depots by collagenase digestion. BAT, interscapular brown adipose tissue; Bra, brain; Int, Intestine; Kid, kidney; Liv, liver; Lun, lung; Mes, mesenteric; Om, omental; T, no template control.
Real-time PCR was used to quantitate the relative levels of Angptl4/FIAF mRNA in the three major WAT depots. There was no significant difference in expression between the subcutaneous, epididymal and perirenal depots, although subcutaneous expression was lower (Fig. 1 (b)). Angptl4/FIAF mRNA level was, however, significantly higher in both the epididymal and perirenal WAT than in the liver. The level of Angptl4/FIAF mRNA in skeletal muscle was considerably lower than in either the liver or the WAT depots, being 50-fold lower than in subcutaneous WAT (Fig. 1(b)).
Adipose tissue is heterogeneous at the cellular level. To determine whether Angptl4/FIAF is expressed solely within adipocytes, or within the stromal vascular fraction as well, cDNA was obtained from samples of subcutaneous, epididymal and perirenal WAT which had undergone digestion with collagenase and separated into the two fractions(Reference Wood, Hunter and Trayhurn26). RT-PCR revealed that Angptl4/FIAF mRNA was present almost exclusively in the adipocytes themselves; only with the perirenal depot was a faint band observed in the stromal vascular fraction (Fig. 1 (c)).
Effect of fasting on the expression of angiopoietin-like protein 4/fasting-induced adipose factor in different tissues
Angptl4/FIAF was originally identified as a gene whose expression was markedly increased in WAT by fasting(Reference Kersten, Mandard, Tan, Escher, Metzger, Chambon, Gonzalez, Desvergne and Wahli6). The depot used was not defined in the original study, and to investigate whether fasting may affect each WAT depot, real-time PCR was used to quantify the changes in expression in tissues of mice following a fast (18 h). Control mice were fed without restriction. The body weight of the fasted mice was on average 23 % lighter than their fed counterparts. Surprisingly, there was no significant increase in Angptl4/FIAF mRNA level in any of the WAT depots tested (Fig. 2 (a)). In marked contrast, there was a substantial increase in Angptl4/FIAF expression in the liver and skeletal muscle, the mRNA level increasing 9·5- and 21-fold in the two tissues, respectively (Fig. 2 (a)).
Effect of an 18 h fast on angiopoietin-like protein 4 (Angplt4) mRNA levels in epididymal (Epi), perirenal (Peri) and subcutaneous (Subcut) white adipose tissue, liver and muscle of CD1 mice. (a) Relative Angplt4 mRNA levels in the Subcut, Peri and Epi depots, and in the liver and skeletal muscle from fed (□) and fasted (
) mice measured by real-time PCR and expressed relative to the corresponding tissue from fed mice. (b) Angptl4/fasting-induced adipose factor (FIAF) abundance was measured in the plasma of fed and fasted mice by western blotting (representative blot); quantified bands are presented in the accompanying bar graph. Values are means with their standard errors depicted by vertical bars (n 7–10). Mean values were significantly different from those of the control group: ***P < 0·001.
To investigate whether the circulating level of Angptl4/FIAF was altered in response to fasting, western blotting was performed on plasma from fed and fasted mice. A strong band of approximately 64 kDa, consistent with Angptl4/FIAF, was detected in each lane (Fig. 2(b)); this band was not detected in blots that had been incubated with either pre-immune serum or secondary antibody alone. Preincubation of the antibody with the peptides against which it was raised also considerably reduced the intensity of the band, providing further evidence that the band detected was indeed Angptl4/FIAF. Densitometric measurements of the band showed no difference in the plasma level between fed and fasted mice (Fig. 2 (b)).
Angiopoietin-like protein 4/fasting-induced adipose factor expression in 3T3-L1 adipocytes
In the next set of experiments the murine 3T3-L1 cell line was used to directly examine the regulation of Angptl4/FIAF expression in adipocytes in vitro. First, the expression of Angptl4/FIAF was determined throughout the maturation of 3T3-L1 cells into mature adipocytes using RT-PCR and compared to that of adiponectin and leptin, two markers of adipocyte differentiation. Angptl4/FIAF mRNA was detected both before and after the induction of differentiation, whereas adiponectin and leptin mRNA were only detected from day 2 post-induction (Fig. 3 (a)).
Angiopoietin-like protein 4/fasting-induced adipose factor (Angptl4/FIAF) gene expression during the differentiation and development of 3T3-L1 cells into adipocytes. (a) Angptl4/FIAF, adiponectin and leptin mRNA expression detected by RT-PCR in 3T3-L1 cells; differentiation was induced at day 0. (b) Relative Angptl/FIAF mRNA levels measured by real-time PCR in 3T3-L1 cells. Values are means with their standard errors depicted by vertical bars (n 6).
Real-time PCR was then used to quantify Angptl4/FIAF mRNA levels in 3T3-L1 adipocytes (Fig. 3 (b)). Angptl4/FIAF expression was low pre-differentiation, and apart from day 2 where a peak in expression was observed (which may be a specific response to components of the induction cocktail), the mRNA level increased gradually after differentiation, being 6-fold greater by day 8. Although there was some variation between days 8 and 18, Angptl4/FIAF expression remained relatively constant and did not change greatly until day 20.
The medium was subsequently examined by western blotting to determine whether Angptl4/FIAF protein was secreted from the 3T3-L1 adipocytes. The pattern of Angptl4/FIAF in the medium was generally similar to the pattern of gene expression in the cells: Angptl4/FIAF could be detected in the medium prior to differentiation with levels increasing post-differentiation (Fig. 4). The level of Angptl4/FIAF in the medium was highest at day 18, at which point it had increased nearly 6-fold over the pre-induction level.
Angiopoietin-like protein 4/fasting-induced adipose factor (Angptl4/FIAF) protein secretion during differentiation and development of 3T3-L1 cells into adipocytes. Angptl4/FIAF abundance was measured in the media of cells at 2 d intervals throughout by western blotting. A representative blot is shown and quantification of the bands is shown in the accompanying bar graph. Values are means with their standard errors depicted by vertical bars (n 3).
Regulation of angiopoietin-like protein 4/fasting-induced adipose factor gene expression in 3T3-L1 cells
Angptl4/FIAF is thought to be involved in energy regulation and is an inhibitor of LPL(Reference Ge, Cha, Gopal, Harp, Yu, Repa and Li10, Reference Yoshida, Shimizugawa, Ono and Furukawa11, Reference Yu, Burgess, Ge, Wong, Nassem, Garry, Sherry, Malloy, Berger and Li14). To determine whether Angptl4/FIAF is regulated by factors that are involved in energy homeostasis, 3T3-L1 cells were treated with insulin, leptin, the synthetic glucocorticoid dexamethasone and noradrenaline for 24 h. A set of cells was also treated with rosiglitazone given the reports that Angptl4/FIAF is induced by PPARγ agonists. Neither leptin nor noradrenaline had any effect on Angptl4/FIAF mRNA levels (Fig. 5 (a)). Treatment with dexamethasone led to a small decrease in mRNA level, to approximately half the control value, while insulin resulted in a modest 1·5-fold increase at both doses; however, this increase was only statistically significant at the higher dose (Fig. 5 (a)). In marked contrast, treatment with rosiglitazone strongly stimulated Angptl4/FIAF expression, the mRNA level increasing more than 8·5-fold at both doses (Fig. 5 (a)).
Effect of rosiglitazone (Rosi), dexamethasone (Dex), insulin, leptin and noradrenaline (NA) on angiopoietin-like protein 4/fasting-induced adipose factor (Angptl4/FIAF) levels in 3T3-L1 adipocytes. Cells were treated at day 10 after induction of differentiation and incubated for 24 h in medium to which different amounts of each agent were added (, low dose; 
, high dose); control cells (□) received no addition. (a) Rosi low dose 0·1 μm; Rosi high dose 1 μm; Dex low dose 2 nm, Dex high dose, 20 nm; Insulin low dose 1 μm; insulin high dose 10 μm; leptin low dose 0·1 μm, leptin high dose 2 μm; NA low dose 0·1 μm, NA high dose 1 μm. Values for Angptl4/FIAF mRNA levels, measured by real-time PCR, are expressed relative to their respective controls. (b) Angptl4/FIAF abundance in the media of cells treated with rosiglitazone was measured by western blotting. Total protein from duplicate samples were pooled and loaded on to each lane. Quantified bands are presented in the accompanying bar graph. Values are means with their standard errors depicted by vertical bars (n 5–6). Mean values were significantly different from those of the control group: *P < 0·05, **P < 0·01, ***P < 0·001.
The medium was examined to determine whether the increase in Angptl4/FIAF mRNA level in the cells induced by rosiglitazone was paralleled by a rise in the amount of the encoded protein released. The identification of the bands detected as Angptl4/FIAF was confirmed by using a second antibody raised in chickens (Aves-lab) against the peptide sequence QYFHSIPRQRQERKK located near the C-terminal of mouse Angptl4. Quantification of the major bands showed that treatment with rosiglitazone for 24 h did not alter the extent of protein secretion into the medium (Fig. 5 (b)).
Recently, it has been shown that Angptl4/FIAF expression is increased in collagen-induced arthritis, an experimental model of inflammatory arthritis(Reference Hermann, Pinkerton, Jennings, Yang, Grom, Sowders, Kersten, Witte, Hirsch and Thornton16). To test whether Angptl4/FIAF expression is mediated by inflammatory agents, the effects of TNF-α, IL-1β, IL-6, IL-10 and IL-18, as well as PGE2, PGF2α, PGI2 and PGD2 on Angptl4/FIAF gene expression were examined (Fig. 6 (a)). TNF-α had no effect on Angptl4/FIAF mRNA level,while IL-1β led to a modest (1·5-fold) increase in level at both doses. Treatment with IL-6, IL-10 and IL-18 led to very small (between 24 and 39 %) decreases in Angptl4/FIAF mRNA level which in some cases were statistically significant (Fig. 6 (a)).
Effect of TNF-α, IL-1β, IL-10, IL-18, IL-6, PGE2, PGF2α, PGI2 and PGD2 on angiopoietin-like protein 4/fasting-induced adipose factor (Angptl4/FIAF) mRNA levels. Cells were taken at day 12 after induction of differentiation and incubated for 24 h in media to which different amounts of each agent were added (, low dose; , high dose). Control cells (□) received no addition. In (a), IL-6, low dose 1 ng/ml, high dose 25 ng/ml; IL-1β, low dose 5 ng/ml, high dose 20 ng/ml, IL-10, low dose 5 ng/ml, high dose 20 ng/ml; IL-18 low dose 100 ng/ml, high dose 500 ng/ml; PGE2, PGF2α and PGD2, low dose 50 μm, high dose 100 μm; PGI2, low dose 50 μm, high dose 150 μm. In (b), the dose response to PGD2 was determined with the cells treated for 24 h in a medium supplemented with 0–150 μm-PGD2. Values for Angptl4/FIAF mRNA levels, measured by real-time PCR, are expressed relative to their respective controls. Values are means with their standard errors depicted by vertical bars (A, n 6; B, n 4). Mean values were significantly different from those of the control group: *P < 0·05, **P < 0·01, ***P < 0·001.
Similar small changes in Angptl4/FIAF mRNA level were also observed when the adipocytes were treated with PGE2, PGF2α and PGI2 (except with the high dose of PGE2, in which a 5-fold decrease in mRNA was observed). Treatment with PGD2, however, led to a major increase in Angptl4/FIAF mRNA level, the increase being 7·2- and 8·5-fold at the low and high doses, respectively (Fig. 6 (a)). To investigate further the effect of PGD2 on Angptl4/FIAF expression, a dose response study was carried out using this PG (Fig. 6 (b)). Treatment with PGD2 led to a significant increase in Angptl4/FIAF mRNA at 50 μm with a peak at 65 μm after which the stimulatory effect of this PG fell.
Dependent upon conditions, PGD2 can spontaneously break down to PGJ2, which may then further convert to either Δ12-PGJ2 or 15-deoxy PGJ2(Reference Fitzpatrick and Wynalda27, Reference Hirata, Hayashi, Ito, Kikawa, Ishibashi, Sudo, Miyazaki, Fukushima, Narumiya and Hayaishi28). Treatment with PGJ2 significantly increased Angptl4/FIAF mRNA level at a concentration of 10 μm in a manner that was generally similar to PGD2, with the level peaking at 50 μm, while at higher doses the stimulatory effect was lost (results not shown).
Discussion
Studies on the physiological role of Angptl4/FIAF have suggested that this protein may be involved in both energy regulation, as a signal of fasting and as an inhibitor of LPL, and in angiogenesis. Angptl4/FIAF is reported to be highly expressed in WAT, brown adipose tissue and liver, with low expression in other tissues(Reference Kim, Kim, Kim, Kim, Park, Uhm, Lee and Koh5–Reference Yoon, Chickering, Rosen, Dussault, Qin, Soukas, Friedman, Holmes and Spiegelman7). In the present study we found that expression of Angptl4/FIAF was evident in all tissues examined, with a strong PCR band detected in each of five different WAT depots, as well as in brown adipose tissue. Thus the Angptl4/FIAF gene is strongly expressed in all the main adipose tissues in mice. Quantitation by real-time PCR indicated that expression was generally higher in WAT than in the liver, and considerably greater than in skeletal muscle.
WAT is a heterogeneous tissue at the cellular level, with mature adipocytes constituting no more than 50 % of the total cell content. Fractionation of WAT indicated that expression is essentially only in the mature adipocytes, there being little or no expression in the cells that constitute the stromal vascular component. Nevertheless, in the cell culture studies on 3T3-L1 adipocytes, some expression was evident prior to the induction of differentiation, albeit less than in the differentiated cells. This may reflect a difference between the clonal cell line and normal preadipocytes, or alternatively may indicate that any contribution from preadipocytes to Angptl4/FIAF mRNA in the stromal vascular fraction is diluted out by the other cellular components (e.g. endothelial cells, macrophages).
The pattern of Angptl4/FIAF expression in 3T3-L1 cells was similar to that observed by Mandard et al. (Reference Mandard, Zandbergen, Tan, Escher, Patsouris, Koenig, Kleemann, Bakker, Veenman, Wahli, Muller and Kersten29). We also found that there was a peak in expression at day 2 post-differentiation, and this may be attributable to a transient stimulation by the components present in the differentiation medium. Secretion of Angptl4/FIAF protein into the culture medium followed a similar overall pattern to that of gene expression, with the amount of protein released being higher post-differentiation and reaching a maximum at around day 14.
Over-expression of Angtpl4/FIAF has been found to inhibit LPL activity(Reference Yoshida, Shimizugawa, Ono and Furukawa11, Reference Yu, Burgess, Ge, Wong, Nassem, Garry, Sherry, Malloy, Berger and Li14, Reference Koster, Chao and Mosior30). Since fasting leads to a fall in LPL activity in WAT(Reference Bergo, Olivecrona and Olivecrona31), and to a reported induction of Angtpl4/FIAF expression in the tissue(Reference Kersten, Mandard, Tan, Escher, Metzger, Chambon, Gonzalez, Desvergne and Wahli6, Reference Yoon, Chickering, Rosen, Dussault, Qin, Soukas, Friedman, Holmes and Spiegelman7), it has been proposed that a key physiological role of Angptl4/FIAF in vivo may be to regulate LPL(Reference Yu, Burgess, Ge, Wong, Nassem, Garry, Sherry, Malloy, Berger and Li14). However, in the present study no change in Angptl4/FIAF expression was observed in three different WAT depots of CD1 mice on fasting (18 h). The reason for this is unclear, but the fall in body weight together with a substantial decrease in leptin mRNA level in WAT (results not shown), indicate that the mice had responded substantially to fasting. Importantly, there was a strong increase in Angptl4/FIAF expression in both liver and skeletal muscle over the same time period, and a 2·5-fold increase in expression has been previously observed in WAT from 12 h fasted C57Bl Ks/J mice(Reference Yoon, Chickering, Rosen, Dussault, Qin, Soukas, Friedman, Holmes and Spiegelman7).
The probable explanation for variations in the response to fasting is in differences between strains of mice. It has been observed that the increase in expression originally observed during fasting may not be observed in WAT from the FVB mice strain(Reference Xu, Lam, Chan, Wang, Zhang, Hoo, Xu, Chen, Chow, Tso and Lam13). In the CD1 strain, Angplt4/FIAF expression has been shown to increase in the omental tissue after a 24 h fast(Reference Backhed, Ding, Wang, Hooper, Koh, Nagy, Semenkovich and Gordon24). The very small size of the omental WAT in mice precluded its use in the present study, but the results suggest that there is no depot-specific regulation in CD1 mice. Overall, since fasting does not consistently induce Angplt4/FIAF expression in mice, the descriptor ‘fasting-induced adipose factor’ would seem inappropriate. Indeed, it could be argued that the impressive 20-fold increase in Angptl4/FIAF mRNA level in skeletal muscle with fasting suggests that the protein is in practice a ‘fasting-induced muscle factor’.
The effect of fasting on Angptl4/FIAF expression in skeletal muscle is intriguing in view of the fact that LPL activity in muscle increases with fasting(Reference Kern32). This raises questions on the putative role of Angplt4/FIAF as an inhibitor of LPL, but it should be noted that even after fasting the Angptl4/FIAF mRNA level in skeletal muscle was still only half that of the subcutaneous WAT depot of fed mice. There was no detectable change in Angptl4/FIAF level in the plasma of the CD1 mice after a 18 h fast, suggesting that in this strain WAT may be the main source of the circulating protein. The size of the band detected in the plasma was 64 kDa, which is a higher molecular weight than that observed with the 3T3-L1 cells; this is probably due to differences in the extent of glycosylation of the protein.
Cell culture was used to investigate the regulation of Angptl4/FIAF expression in adipocytes. The range of agents examined reflect the proposed physiological roles of Angptl4/FIAF and include those involved in energy homeostasis, inflammation and angiogenesis. Treatment with agents such as insulin and leptin that are involved in energy homeostasis had little effect on Angptl4/FIAF expression, although incubation with the synthetic glucocorticoid, dexamethasone, led to a 2-fold reduction in the mRNA level. The glucocorticoids have anti-inflammatory actions, inhibiting the expression of TNF-α and other pro-inflammatory factors. Dexamethasone is also known to inhibit the activity of Cox-2, an enzyme involved in the synthesis of PG(Reference Tordjman, Coge, Andre, Rique, Spedding and Bonnet33, Reference Bell-Parikh, Ide, Lawson, McNamara, Reilly and FitzGerald34).
During fasting, there is a marked increase in sympathetic activity to WAT(Reference Migliorini, Garofalo and Kettelhut35), which stimulates lipolysis and suppresses leptin expression(Reference Bartness and Bamshad36, Reference Trayhurn, Duncan, Hoggard and Rayner37). Given the initial observations that Angptl4/FIAF expression in WAT was induced by fasting it was considered that the sympathetic system might play a key role in the regulation of Angptl4/FIAF synthesis. However, noradrenaline had no effect on Angptl4/FIAF mRNA level, and as discussed we were unable to observe a fasting-induced expression of Angptl4/FIAF in WAT.
Treatment of cells with the PPARγ agonist rosiglitazone led to a large stimulatory effect on Angptl4/FIAF expression, as in previous studies(Reference Kersten, Mandard, Tan, Escher, Metzger, Chambon, Gonzalez, Desvergne and Wahli6, Reference Yoon, Chickering, Rosen, Dussault, Qin, Soukas, Friedman, Holmes and Spiegelman7). However, the stimulatory effect of rosiglitazone on gene expression was not mirrored in the level of Angptl4/FIAF secreted into the media, which remained unchanged. It is probable that the absence of an increase in secretion reflects the lag between alterations in gene expression and the translation and subsequent release of the mature protein product. This seems likely since increases in the level of Angptl4/FIAF in the medium have been observed following treatment of cells with PPAR agonists for 48 rather than 24 h(Reference Hirata, Hayashi, Ito, Kikawa, Ishibashi, Sudo, Miyazaki, Fukushima, Narumiya and Hayaishi28).
There was little effect on Angptl4/FIAF expression when 3T3-L1 adipocytes were treated with the pro-inflammatory cytokine TNF-α, or with IL-1β, IL-6, IL-10 and IL-18; several of these factors are expressed by WAT and their circulating level is increased in the mild inflammatory state of obesity(Reference Rajala and Scherer3, Reference Trayhurn and Wood4, Reference Trayhurn and Wood38). The only inflammation-related agents that affected Angptl4/FIAF expression were the inflammatory PGD2 and its derivative. There are limited reports on the effect of PG on WAT function, but it has recently been shown that PGD2 and the J2 series PG modulate the expression and secretion of IL-6, leptin, MCP-1 and nerve growth factor in 3T3-L1 adipocytes(Reference Bullo, Peeraully and Trayhurn39, Reference Peeraully, Sievert, Bullo, Wang and Trayhurn40).
In conclusion, the present study demonstrates that the adipokine Angptl4/FIAF is strongly expressed in each of the main adipose tissue depots of mice. Since fasting for 18 h did not lead to any induction of Angptl4/FIAF expression in WAT, in contrast to the liver and skeletal muscle, it is unlikely that the protein can act as an adipose tissue-derived signal of overall nutrient status.
Acknowledgements
We are grateful to Mr Leif Hunter for his help and advice and to the Biotechnology and Biological Sciences Research Council (UK) for funding.
